2019165438+16 October, an innovative anti-influenza drug with a brand-new mechanism-xofluza (chemical name: mabaloxavir tablets) made its debut in the domestic public. At the same time, Roche Pharmaceuticals China also signed a strategic cooperation agreement with Hainan Lecheng International Medical Tourism Pioneer Zone, taking the lead in adopting the "try first" policy in Hainan Free Trade Zone, and bringing Xofluza, the world's first innovative anti-influenza drug approved by FDA in the past 20 years, into Hainan Pioneer Zone. This cooperation will realize the clinical application of "special imported drugs for anti-influenza treatment" in Hainan Free Trade Zone Hospital for the first time through bonded drug storehouse. Xofluza is an innovative anti-influenza drug with a brand-new mechanism of action. It is one of the most serious and common infectious diseases in the world, which seriously threatens public health and safety. According to the data of the World Health Organization, every year, seasonal influenza will cause 3 million to 5 million people worldwide to be hospitalized due to related serious diseases, and lead to 290,000 to 650,000 deaths. A global epidemic will kill millions of people. Professor Lu Hongzhou, Party Secretary of Public Health Clinical Center affiliated to Fudan University in Shanghai and Chief Physician of Infectious Diseases Department of Huashan Hospital affiliated to Fudan University, pointed out: "Vaccine is the most effective means to prevent influenza, but antiviral drug treatment still plays an important role in influenza prevention and treatment. In particular, antiviral treatment within 48 hours after flu symptoms appear can effectively help relieve patients' symptoms and shorten the course of disease. At present, the widely used oral anti-influenza drug is neuraminidase inhibitor antiviral drug (oseltamivir), which needs to be taken twice a day for 5 days. Xofluza with a new mechanism of action can directly inhibit virus replication, and patients can stop virus detoxification within 24 hours after taking it once. Many clinical studies have proved that Xofluza can significantly shorten the time for patients to relieve/improve symptoms and reduce the risk of infection after exposure to influenza. Compared with the current neuraminidase inhibitor anti-influenza drugs, Xofluza can further shorten the virus detoxification time by about 2 days. In addition, Xofluza shows good safety in children, adults and the elderly. At present, Xofluza has been approved in 9 countries and regions around the world, and it has been approved for treating influenza A or B virus infection in Japan. In the United States, Singapore, Thailand, China, Hongkong and Taiwan Province Province, it is used for 12-year-old and above patients with acute uncomplicated influenza with symptoms less than 48 hours. China Drug Administration also approved Xofluza to carry out clinical trials in China. According to the normal application approval procedures, Xofluza is expected to take several years to fully enter China. The signing of this contract will mean that with the help of China's new policy of opening to the outside world, Xofluza, a new anti-influenza drug, will meet patients in Chinese mainland in advance. With the help of the new policy of free trade zone opening, innovative drugs will meet patients in Chinese mainland in advance. In response, the State's Guiding Opinions on Supporting Hainan's Comprehensive Deepening of Reform and Opening-up will be implemented, and the construction of Boao Lecheng International Medical Tourism Pioneer Zone will be comprehensively promoted. During this year's China International Import Expo (CIIE), Roche Pharmaceutical China also signed a strategic cooperation agreement with Hainan Boao Lecheng International Medical Tourism Pioneer Zone Administration, which will use the "try first" policy in the Free Trade Zone to promote innovative drugs of Roche that have not been approved for marketing in Chinese mainland to enter Hainan Boao Lecheng Tourism Pioneer Zone for pre-marketing clinical application and product display, so as to meet the actual clinical needs of patients and promote these innovative drugs to enter China more quickly. Gu Gang, director of Hainan Boao Lecheng International Medical Tourism Pioneer Zone Administration, said: "In order to fully implement and improve Boao Lecheng's international medical tourism pioneer zone policy and explore a new engine of sustainable development, the pioneer zone has made many explorations in medical model innovation. By signing the framework agreement with Roche Pharmaceuticals this time, we hope to introduce more innovative drugs into the pioneer area, so that more patients in China can enjoy the most advanced treatment in the world without going abroad. We also hope that more innovative drugs from other companies will enter the pioneer area. Isabella Chow, President of Roche Pharmaceuticals in China, said, "This is the second time Roche has participated in China International Import Expo (CIIE), and we are very happy to use this platform to showcase Roche's latest innovative drugs. Thanks to the accelerating opening up of China, we are also honored to sign a cooperation agreement with the pioneer zone of Lecheng. With the good policies of Hainan Free Trade Zone, we hope that these innovative drugs can help China patients who are in urgent need more quickly. In the future, Roche will, as always, practice its long-term commitment of "basing itself on China and serving China" with practical actions to benefit more China patients. André Hoffmann, representative of Roche's founding family and vice chairman of the board of directors of Roche Group, said: As a leader of personalized medical care, Roche has brought innovative products and solutions of "integrated diagnosis and treatment" to China International Import Expo (CIIE), and we are honored to participate in China International Import Expo (CIIE) again to promote the development of innovation ecosystem in China and even the world. China has an important strategic position in Roche's global strategy. Thanks to Roche's strong product lineup, dedicated talent team and persistent persistence in sustainable development, we are very confident to bring more innovative products to China for the benefit of more patients in the long-term development of China. ▲ Disclaimer: The above content comes from the Internet, and the copyright belongs to the original author. If there is any infringement of your original copyright, please let us know and we will delete the relevant content as soon as possible.